首页> 中文期刊> 《中国卫生标准管理》 >芪参益心方治疗风湿性心脏病慢性心力衰竭临床观察

芪参益心方治疗风湿性心脏病慢性心力衰竭临床观察

         

摘要

ObjectiveTo study the effect of the treatment of chronic heart failure patients with rheumatic heart disease in patients with chronic heart failure. Methods According to our hospital from January 2013 to January 2014, 76 cases of rheumatic heart disease patients with chronic heart failure were analyzed, the patients were divided into control group and treatment group, 38 cases. The control group received western medicine treatment, the treatment group received western medicine treatment and the treatment of Qi Shen Yi Xin, the two groups were treated with four courses of treatment, compared the treatment results.ResultsThe effective rate of the control group was 65.79%, the effective rate of the treatment group was 81.58%, the effective rate of the two groups was statisticaly significant (P<0.05); the two groups were compared. The results were excelent in the treatment group than in the control group (P<0.05).Conclusion Rheumatic heart disease with chronic heart failure is a clinical difficult to treat the disease, take the western medicine and the treatment of Qi and the combination of Western medicine and the treatment of the patients with high efficiency, and can be further studied and explored.%目的:研究分析风湿性心脏病慢性心衰患者接受芪参益心方治疗的效果。方法根据2013年1月~2014年1月我院的76例风湿性心脏病慢性心衰患者来进行研究分析,将这些患者分成对照组和治疗组,均有38例。对照组患者接受西药治疗,治疗组接受西药治疗和芪参益心方治疗,两组均接受四个疗程治疗,比较治疗结果。结果对照组治疗有效率是65.79%,治疗组有效率是81.58%,两组的治疗有效率存在统计学差异性(P<0.05);比较分析两组的超声心动图射血分值改善情况,结果为治疗组比对照组优秀(P<0.05)。结论风湿性心脏病慢性心衰是临床中比较难治疗的疾病,采取西药和芪参益心方联合治疗的方式具有比较高的治疗有效率,临床可以进一步的研究和探索。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号